CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

By B. Olsson, Ronald Lautner, U. Andreasson, A. Öhrfelt, E. Portelius, M. Bjerke, M. Hölttä, Christoffer Rosén, C. Olsson, G. Strobel and 5 more. Lancet Neurology, 2016

1,763 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/9b3db5cbd8dab968b8950009220721208cf57ef8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Biomarkers for Alzheimer's disease: current status and prospects for the future (2018, methodology): “amyloid (1-42) assay was published (104).”
Alzheimer's disease (2018, background): “The typical CSF pattern in AD is low Ab42 and elevated levels of both tau and phospho-tau; this pattern also has value in predicting which individuals with MCI will develop AD [58] and as a result is included in diagnostic criteria [59].”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “The most thoroughly examined P-tau epitope as a CSF biomarker for AD is threonine 181 (P-tau181) [143], but assays for the concentration of P-tau231 and P-tau199 correlate tightly with P-tau181 and show very similar diagnostic accuracy [144].”
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018, background): “The Ab(1–42), phosphorylated tau (pTau), and total tau (tTau) CSF biomarkers are able to distinguish patients with AD versus controls as outlined in a recent meta-analysis [15].”
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019, background): “Many studies over the last 2 decades have evaluated plasma Aβ42 as a biomarker for AD, typically using immunoassays with relatively high variance and uncertain specificity, and overall found poor and inconsistent performance.(35) The ratio of plasma Aβ42 to Aβ40, as measured by high-precision assays”
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, background): “372,373 While amyloid and tau PET and CSF biomarkers speci ﬁ cally indicate AD-related pathology, they are not entirely equivalent.”
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. (2021, neutral): “6 However, with the development of highly sensitive assays and technologies, recent results are much more promising.”